APA (7th ed.) Citation

FF, R., VP, B., RC, B., CD, B., MM, C., MS, E., . . . NS, H. (2022). Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulmonary circulation, 12(2), e12055. https://doi.org/10.1002/pul2.12055

Chicago Style (17th ed.) Citation

FF, Rahaghi, et al. "Delphi Consensus Recommendation for Optimization of Pulmonary Hypertension Therapy Focusing on Switching from a Phosphodiesterase 5 Inhibitor to Riociguat." Pulmonary Circulation 12, no. 2 (2022): e12055. https://doi.org/10.1002/pul2.12055.

MLA (9th ed.) Citation

FF, Rahaghi, et al. "Delphi Consensus Recommendation for Optimization of Pulmonary Hypertension Therapy Focusing on Switching from a Phosphodiesterase 5 Inhibitor to Riociguat." Pulmonary Circulation, vol. 12, no. 2, 2022, p. e12055, https://doi.org/10.1002/pul2.12055.